25Aug
Johnson & Johnson Announces Acquisition of Momenta For $6.5 Billion
Johnson and Johnson announced that it has entered into an agreement to acquire Momenta Pharmaceuticals, Inc. for $6.5 billion. The acquisition gives J&J’s Janssen unit full global rights to Momenta’s nipocalimab (M281), an anti-FcRn antibody designed to treat a number of autoantibody-driven disorders, including generalized myasthenia gravis (gMG), warm autoimmune hemolytic anemia (wAIHA), and hemolytic disease of the fetus and newborn (HDFN)....
By:
Goodwin
Related
On April 8, 2020, Governor Murphy signed Executive Order No. 122 (the Order) strengthening mitigatio...
Read More >
Construction workers are permitted to continue working in New Jersey, but projects must reduce onsit...
Read More >
We previously wrote about Riot Games’ $10,000,000 settlement of a class action lawsuit for alleged ...
Read More >
Recognizing that Japan has entered a new phase in its fight against the spread of Coronavirus Diseas...
Read More >
The Department of Justice (DOJ) has settled and obtained judgements in excess of $2.8 billion for fa...
Read More >
A recent settlement between Seattle chef Tom Douglas and his restaurant employees highlights the pot...
Read More >